Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vertex, Inc.

40.19
+0.84002.13%
Pre-market: 39.50-0.6900-1.72%09:17 EDT
Volume:777.37K
Turnover:31.07M
Market Cap:6.36B
PE:-118.38
High:40.56
Open:39.20
Low:39.01
Close:39.35
Loading ...

Vertex Pharmaceuticals (VRTX): One of the Best Biotech Stocks to Buy According to Billionaires

Insider Monkey
·
18 Mar

Goldman Sachs Analyst Anticipates Clarity On Vertex's Investment Roadmap And Product Monetization At Investor Day

Benzinga
·
18 Mar

Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock?

Zacks
·
17 Mar

3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now

Motley Fool
·
14 Mar

Cryptocurrency Payment Platform RedotPay Completes $40 Million Series A Funding Round, Led by Lightspeed

Blockbeats
·
14 Mar

Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today

Zacks
·
14 Mar

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
14 Mar

GILD vs. VRTX: Which Stock Is the Better Value Option?

Zacks
·
13 Mar

Vertex, Inc. to Host 2025 Investor Day

GlobeNewswire
·
12 Mar

Company News for Mar 11, 2025

Zacks
·
11 Mar

Where Will Vertex Pharmaceuticals Be in 10 Years?

Motley Fool
·
11 Mar

Analysts’ Top Healthcare Picks: BridgeBio Pharma (BBIO), Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
11 Mar

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
11 Mar

If I Could Buy Only 1 Growth Stock, This Would Be It

Motley Fool
·
10 Mar

3 Magnificent Growth Stocks to Buy in March

Motley Fool
·
08 Mar

Vertex Pharmaceuticals (NasdaqGS:VRTX) Gains UK Approval For New Cystic Fibrosis Treatment

Simply Wall St.
·
08 Mar

Vertex Pharmaceuticals Gets UK Regulatory Approval for Alyftrek to Treat Cystic Fibrosis

MT Newswires Live
·
07 Mar

Vertex Pharmaceuticals announces MHRA approval of ALYFTREK for CF

TIPRANKS
·
07 Mar

Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

Business Wire
·
07 Mar

Vertex Pharmaceuticals' Triple Combination Cystic Fibrosis Therapy Alyftrek Receives Approval in UK

MT Newswires Live
·
07 Mar